Literature DB >> 25525851

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report.

Alberto Bongiovanni1, Marianna Ricci, Nada Riva, Sebastiano Calpona, Devil Oboldi, Federica Pieri, Davide Cavaliere, Laura Mercatali, Chiara Liverani, Federico La Manna, Alessandro De Vita, Flavia Foca, Erica Gunelli, Dino Amadori, Toni Ibrahim.   

Abstract

Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.

Entities:  

Keywords:  gastrointestinal stromal tumor; imatinib; metastatic gastrointestinal stromal tumor; pleural effusion; toxicity

Mesh:

Substances:

Year:  2014        PMID: 25525851     DOI: 10.2217/fon.14.159

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.

Authors:  Julien Mahé; Emilie Patras de Campaigno; Anne-Laure Chené; Jean-Louis Montastruc; Fabien Despas; Pascale Jolliet
Journal:  Br J Clin Pharmacol       Date:  2018-08-05       Impact factor: 4.335

2.  Imatinib-induced pleural effusion: A case report.

Authors:  R Banka; Z Udwadia
Journal:  J Postgrad Med       Date:  2017 Jan-Mar       Impact factor: 1.476

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.